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2 Abbrevations 
 
AMP    Adenosine Monophosphate 
AP-1    Activator Protein 1 
ATP    Adenosine Triphosphate  
B    Bartonella 
BGA     Blood Gas Analysis 
CD73    Ecto-5’-nucleotidase 
COX-2   Cyclooxygenase 2 
DNA    Deoxyribonucleic Acid 
DTT    Dithiothreitol 
EBV    Epstein Barr Virus 
ECM    Extracellular Matrix 
ELISA    Enzyme-Linked Immunosorbent Assay 
ES    Embryonic Stem 
EPO    Erythropoietin 
FN-1    Fibronectin 1 
HBV    Hepatitis B Virus 
HBx    Hepatitis B Virus x Protein 
HHV-8   Human Herpesvirus 8 
HIF-1     Hypoxia Inducible Factor 1 
HRE    Hypoxia Responsive Element 
HRP    Horseradish Peroxidase 
IGF    Insulin-like Growth Factor 
IGFBP   Insulin-like Growth Factor Binding Protein 
IL    Interleukin 
KCl    Kaliumchlorid 
KSHV    Kaposi’s Sarcoma-Associated Herpesvirus 
MOI    Multiplicity of Infection 
mRNA   Messenger Ribonucleic Acid 
NaCl    Natriumchlorid 
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NF-IL6   Nuclear-Factor-IL6  
NF-κB    Nuclear factor kappa B 
O2    Oxygen 
pO2    Oxygen Partial Pressure 
OV    Orthovanadate 
PBS    Phosphat Buffered Saline 
PCR    Polymerase Chain Reaction 
PFU    Plaque-Forming Units 
PMSF    Phenylmethylsulfonyl Fluoride 
RIPA    Radio-Immuno Precipitation Assay 
RNA    Ribonuclein Acid 
siRNA    Small Interfering Ribonuclein Acid 
RSV    Respiratory Syncytial Virus 
RT-PCR   Realtime Polymerase Chain Reaction 
TBS    Tris Buffered Saline 
UV    Ultraviolet 
VEGF    Vascular Endothelial Growth Factor 
VHL    von Hippel-Lindau 
VSV    Vesicular Stomatitis Virus 
Y    Yersinia 
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3 Introduction 
This first chapter gives a general introduction to the thesis’s subject. The terms 
and concepts used throughout this work are explained and put in context. The 
role of Hypoxia-inducible factor 1 (HIF-1) in cellular regulation mechanisms is 
illustrated, and its interrelation with inflammation and infection is shown. We 
also introduce and discuss the target genes regulated by HIF-1.  
Finally, we provide a section on Respiratory Syncytial Virus (RSV) where we 
show the classification and effects of the virus.  
 
3.1 Preface 
Hypoxia-inducible factor 1 (HIF-1) is a transcription factor that functions as a 
master regulator of mammalian oxygen homeostasis and also as a 
transcriptional regulator during inflammation and infection with different 
pathogens. HIF-1 activity is induced in a variety of cell types and HIF-1 
stabilization can occur via oxygen-dependent (69) or oxygen independent (56) 
pathways. HIF-1 has been found to regulate the transcription of multiple genes 
that include hypoxia responsive elements (HRE) in their promoter regions in a 
cell type specific manner.  
Whereas HIF-1 was originally discovered as a biologic oxygen sensor that 
enables the organism to adapt to hypoxia, recent studies have shown that it 
plays a central role in cellular responses beyond hypoxia. These include not 
only inflammation and infection but also angiogenesis of tumors, cell 
proliferation, glucose and iron metabolism (58, 83).  
 
Respiratory syncytial virus (RSV) is the major etiologic agent of severe 
epidemic lower respiratory tract infections in infancy. Beyond that, it is 
amongst the most potent biological stimuli to induce an inflammatory milieu. 
Infection with RSV is rapidly followed by a network of cellular responses. Acute 
bronchiolitis, a severe clinical manifestation of RSV infection is characterized 
by wheezing, respiratory distress, and the pathologic findings of peribronchial 
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cell infiltration and release of inflammatory mediators (100). In addition to the 
acute morbidity of RSV infection, there are long-term consequences: RSV has 
been shown to predispose to the development of hyperreactive airway disease 
and recurrent episodes of wheezing are often precipitated by subsequent RSV 
infection (54, 127). 
 
Previous studies have shown increased levels of HIF-1α during bacterial, viral 
and parasital infections. These findings led us to explore the  
HIF-1 pathway during infection with RSV. We hypothesized a role of HIF-1 as 
transcriptional regulator during infections with respiratory syncytial virus and 
pursued HIF-1 activation and gene-transcription during RSV infection.  
 
3.2 Transcription factors  
Transcription factors are proteins that bind to regulatory sequences, usually in 
the 5’ upstream promoter region of target genes, to increase (or sometimes 
decrease) the rate of gene transcription. This may result in increased or 
decreased protein synthesis and altered cellular function (8).  
Transcription factors can be activated by many extracellular influences, but 
may also be directly activated by ligands. They act as “nuclear messengers” 
and can convert transient environmental signals at the cell surface into long-
term changes in gene transcription (7). In the context of inflammatory 
diseases, transcription factors activated by inflammatory stimuli (such as 
cytokines or viruses) switch on inflammatory genes. This leads to increased 
synthesis of inflammatory proteins. In this way, transcription factors may 
amplify and perpetuate the inflammatory process.  
Several families of transcription factors exist. The members of each family 
share structural characteristics (103). Whereas many transcription factors are 
ubiquitous, others are cell specific and determine the phenotypic 
characteristics of a cell (8).   
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3.3 Hypoxia inducible factor 
A number of elegant studies, exemplified by those defining induction of the 
erythropoietin (EPO) gene (16, 120), have utilized multidisciplinary approaches 
to elucidate basic hypoxia-adaptive responses. Today, convincing evidence 
confirms a central role of hypoxia-inducible factor (HIF)-1 in mammalian 
oxygen homeostasis (107, 117, 125, 126).  
Such studies demonstrated that HIF-1 is a heterodimeric helix-loop-helix 
transcription factor composed of two subunits: constitutively expressed HIF-1β 
and oxygen-regulated HIF-1α (147). Under normoxic conditions, HIF-1α is 
continuously synthesized and subjected to hydroxylation on proline residues 
(118). The modification is required for the binding of the von Hippel-Lindau 
(VHL) tumor suppressor protein, the recognition component of an E3 ubiquitin-
protein ligase that targets HIF-1α for proteasomal degradation. Under hypoxic 
conditions, hydroxylation is inhibited and the VHL protein does not bind to HIF-
1, eventually leading to stabilization of the alpha-subunit, heterodymerization, 
nuclear translocation and transcription of HIF-dependent genes (88, 150). In 
the absence of hydroxylation due to hypoxia, HIF-1 translocates to the nucleus 
and binds to hypoxia responsive elements (HRE) in the regulatory regions of 
target genes and affects the rate of gene transcription. 
 
In keeping with the complexity of the hypoxic response, three principal 
isoforms of HIFα exist: HIF-1α, HIF-2α and HIF-3α (150).  
The HIF-2α protein is structurally similar to HIF-1α, dimerizes with HIF-1β, and 
contains proline and asparagine residues that are hydroxylated in an oxygen-
dependent manner. Unlike HIF-1α, which is active in all hypoxic cells, HIF-2α 
only appears to be transcriptionally active in a restricted number of cell types 
(119). HIF-3α is less closely related and its role is not yet fully understood 
(150).  
 
HIF-1 was originally discovered as a biologic oxygen sensor that enables the 
organism to adapt to hypoxia. Under baseline conditions, normal tissues show 
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little evidence of HIF-1 activation (132). When oxygen levels fall, HIF-1α is 
activated by post-transcriptional changes in its stability and transcriptional 
activity (89). The half-life of HIF-1α is regulated in an oxygen-dependent 
manner (115) and the posttranslational modifications of HIF-1α are rapidly and 
precisely modulated according to the cellular oxygen concentration by 
multiprotein complexes. In non-hypoxic cells (cultured in 20% O2), there is no 
detectable HIF-1α protein. When cells are transferred to hypoxic conditions 
(1% O2), HIF-1α expression can be detected within 30 minutes (121). Previous 
studies demonstrated a time- and O2 concentration-dependent manner of the 
HIF-1α induction in cells exposed to hypoxia (153).  
 
Up-regulation of HIF-1α was also observed in a broad range of cancers 
including breast and prostate cancer which was correlated well with increased 
vascularity and metastatic potential, indicating that the expression of HIF-1α is 
associated with tumor progression (26, 154). The expression of HIF-1α is of 
primary importance in angiogenesis, tumor growth, invasion and metastasis. 
The expression of HIF-1α is high in many carcinoma cells compared to normal 
tissues and it is an essential transcription factor for different factors and 
enzymes that are required for the continued growth and survival of tumors 
(152). This is a result of genetic alterations and intratumoral hypoxia (154).  
 
The HIF system provides a molecular basis for understanding a set of classical 
physiological responses. It is evident that HIF shapes very extensive aspects 
of development, physiology and disease, providing cells with a master 
regulator that coordinates changes in gene transcription.  
 
The following figure gives an illustration of the HIF-1α pathway.  
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Regulation of HIF-1α protein  
Under normoxic conditions, hydroxylation on proline residues allow capture of 
HIF-1α by the von Hippel Lindau (VHL) protein. An ubiquitin-protein ligase (UL) 
targets HIF-1α to proteasomal degradation.  
In the absence of hydroxylation due to hypoxia, HIF-1α translocates to the 
nucleus, heterodimerizes with HIF-1β and binds to hypoxia-responsive 
elements (HRE) in the regulatory regions of target genes. 
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3.4 Hypoxia 
Oxygen is required by the cells of most organisms to produce adequate 
amounts of Adenosine Triphosphate (ATP) necessary for metabolic activities.  
Decreased oxygenation causes the tissues to become hypoxic, and this in turn 
initiates a variety of signals and produces alterations in many physiological 
parameters. These are well-known and have been extensively documented 
(89). Oxygen has therefore been identified as a major control element in 
cellular processes (1). Hypoxia occurs within human tissues and cells due to 
many different conditions, including disorders of the heart and lungs, anemia, 
and circulatory problems. Depending on the severity, permanent damage to 
tissues and cells may occur (114). However, hypoxia also can play an 
important and beneficial role in human physiology and development (155). 
Many organisms have evolved adaptive mechanisms for hypoxic conditions. 
Changing oxygen levels can result in activation or repression of certain 
homeostatic regulatory genes, allowing for the survival of tissues and cells 
despite fluctuating environmental conditions. Genes whose activation is 
prompted by hypoxic conditions, can interact with enzymes and other 
transcriptional factors in order to control vascularization and tissue growth. 
While microenvironments surrounding cancerous tumors are extremely 
hypoxic, proliferation of such masses is often made possible by HIF-1 
activation. This leads to increased angiogenesis and, thus, an increased 
oxygen supply to the area (18).  
However, in hypoxic environments, there is a shift to anaerobic metabolism for 
cellular energy production. HIF-1 is among the principal genes to coordinate 
this shift, by inducing a variety of glycolytic enzymes and glucose transporters. 
This helps cells to efficiently produce energy in hypoxic environments (18, 
143).  
 
During inflammatory processes, we find significant changes in tissue 
metabolism. In particular, metabolic shifts during inflammation can result in 
significant tissue hypoxia. Prior studies assume hypoxia in infected cells due to 
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increased oxygen consumption. It has been shown that this causes 
stabilization of HIF-1. However, other studies of HIF-1 during inflammation and 
infection have found oxygen-independent activation of HIF-1 during infections 
with human pathogens (56).  
 
3.5 HIF-1 and Inflammation 
Active inflammation is characterized by dramatic shifts in tissue metabolism. 
These changes include diminished availability of oxygen (hypoxia) (45) with 
subsequent lactate accumulation and resultant metabolic acidosis. A number 
of studies have implicated hypoxia in mucosal inflammatory diseases such as 
colitis (57, 77). Other studies in murine models identified the epithelium as the 
central target of hypoxia during active inflammation (66).  
 
In the meantime, a number of studies have identified HIF-1 as transcriptional 
regulator of inflammation and infection. For example, HIF-1 is essential for 
myeloid cell-mediated inflammation, bactericidal capacity of phagocytes (105) 
and mice with conditional knockouts of HIF-1 show profound impairment of 
myeloid cell aggregation, motility, invasiveness, and bacterial killing (25). 
Moreover, studies of HIF-1 during infection with enterobacteriaceae revealed 
hypoxia-independent activation by bacterial siderophores (56). Similarly, HIF-1 
has been identified as key regulator of the inflammatory transcription factor 
Nuclear factor kappaB (NF-κB) (145). Other studies confirmed several parallels 
between the transcriptional regulation of hypoxia and inflammation/infection 
(34, 56, 69, 78, 94). For example, a recent study suggests that NF-κB is a 
critical transcriptional activator of HIF-1 and that basal NF-κB activity is 
required for HIF-1 protein accumulation under hypoxia (108). Similarly, studies 
of human pathogenes have revealed that exposition of host cells to bacteria 
(e.g. Bartonella henselae) results in HIF-1 activation and VEGF secretion in 
vivo and in vitro (69). Similar findings were reported when macrophages were 
infected with group B streptococci (25, 105).  
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In conclusion it can be said that HIF-1 obviously plays a central role in 
infections with human pathogens.  
 
This might have important medical implications in terms of the treatment of 
sepsis. For example, it has been shown that serum VEGF levels (known to be 
regulated via HIF-1) are dramatically increased in patients suffering from 
septicemia (142) or meningitis (141). 
 
3.6 HIF-1 target genes 
HIF-1 acts as a master regulator of oxygen-regulated gene expression and 
regulates the transcription of hundreds of genes in a cell type specific manner 
(88). For example, binding of HIF-1 to consensus domains in the erythropoitin 
promoter results in the transcriptional induction of HIF-1-bearing gene 
promoters (116). A series of experiments by Wang and Semenza (147-149) 
and Maxwell et al. (91) has demonstrated that reporter genes containing the 
erythropoitin enhancer were induced by hypoxia in a variety of cell types that 
did not normally produce erythropoitin. Subsequently, it was determined that 
HIF-1 is widely expressed and that consensus HIF-1 binding sequences exist 
in a number of genes other than that of erythropoitin, and were termed hypoxia 
responsive elements (HRE (116)). When this sequence was introduced into a 
heterogous reporter gene and transfected into cultured cells, there was a 
dramatic increase in reporter gene trenscription when the cells were exposed 
to hypoxia (121). In particular, HIF-1 has been found to regulate multiple genes 
that include HRE in their promoter region, including vascular endothelial 
growth factor (VEGF), insuline-like growth factors (IGFs), their binding proteins 
[insuline-like growth factor binding proteins (IGFBPs)] and iron supply 
regulating genes [e.g. transferrin (113)]. HIF-1 binds to the hypoxic responsive 
elements (HRE) of target gene regulatory sequences, resulting in the 
transcription of these genes.   
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The discovery of HIF-1 represented a major advance in the understanding of 
gene regulation by hypoxia. Different studies on the role of HIF-1 in cellular 
processes have established the general agreement that induction of HIF-1 
responsive genes drives a variety of effects. These include altered cellular 
metabolism, increased vascular mass and diameter and increased oxygen 
carrying capacity of the blood. All of these effects are conducive to an adaptive 
response to diminished oxygen supply (18, 44, 80, 120).  
HIF-1 activation is capable of mediating a response that is precisely tailored to 
the requirements of the cell, tissue and organism.  
 
Table 1 (83) presents a structured overview of the genes that get 
transcriptionally activated by HIF-1. It also shows the rich variety of functions 
of the genes regulated by HIF-1.   
 
From the wealth of genes regulated by HIF-1, we have used four genes 
exemplarily in our study. These four genes will be discussed in detail in the 
sections following Table 1.  
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Table 1: Transcriptionally activated genes by HIF-1 (83) 
 
Function    Genes 
 
Cell proliferation   Cyclin G2, IGF2, IGF-BP1, IGF-BP2, IGF- 
BP3, WAF-1, TGFα, TGFβ3 
Cell survival    ADM, EPO, IGF2, IGF-BP 1-3, NOS2, TGFα,  
VEGF 
Apoptosis    NIP3, NIX, RTP801 
Motility    ANF/GPI, c-MET, LRP1, TGFα 
Cytoskeletal structure  KRT14, KRT18, KRT19, VIM 
Cell adhesion   MIC2 
Erythropoieseis   EPO 
Angiogenesis   EG-VEGF, ENG, LEP, LRP1, TGF-β3, VEGF 
Vascular tone   α1B-adrenergic receptor, ADM, ET1, Haem  
oxygenase-1, NOS2 
Transcriptional regulation  DEC1, DEC2, ETS-1, NUR77 
pH regulation   Carbonic anhydrase 9 
Regulation of HIF-1 activity P35srj 
Epithelial homeostasis  Intestinal trefoil factor 
Drug resistance   MDR1 
Nucleotide metabolism  Adenylate kinase 3, Ecto-5’-nucleotidase 
Iron metabolism   Ceruloplasmin, Transferrin,  
Transferrin receptor 
Glucose metabolism  HK1, HK2, AMF/GPI, ENO1, GLUT1,  
GAPDH, LDHA, PFKBF3, PFKL, PGK1,  
PKM, TPI, ALDA, ALDC 
Extracellular-matrix metabolism CATHD, Collagen type V (α1), FN1, MMP2,  
PAI1, Prolyl-4-hydroxylase α (1), UPAR 
Energy metabolism   LEP 
Amino-acid metabolism  Transglutaminase 2 
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ADM   adrenomedullin 
ALDA   aldolase A 
ALDC   aldolase C 
AMF   autocrine motility factor 
CATHD  cathepsin D 
EG-VEGF  endocrine-gland-derived VEGF 
ENG   endoglin 
ET1   endothelin1 
ENO1   endolase1 
EPO   erythropoietin 
FN1   fibronectin 
GLUT   glucose transporter 
GAPDH  glyceraldehyde-3P-dehydrogenase 
HK   hexokinase 
IGF   insulin-like-growth factor 
IGF-BP  IGF-binding protein 
KRT   kreatin 
LDHA   lactate dehydrogenase 
LEP   leptin 
LRP1   LDL-receptor-related protein 
MDR   mulitdrug resistance 
MMP   matrix metalloproteinase 
NOS2   nitric oxide synthase 
PFK   phosphofructokinase 
PGK   phosphoglycerate kinase 
PAI   plasminogen-activator inhibitor 
PKM   pyruvate kinase M 
TGF   transforming growth factor 
TPI   triosephosphate isomerase 
VEGF   vascular endothelial growth factor 
UPAR   urokinase plasminogen activator receptor 
VEGFR2  VEGF-receptor2 
VIM   vimentin 
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3.6.1 CD73 
Ecto-5’-nucleotidase (CD73) is a membrande-bound glycoprotein that 
functions to hydrolyze extracellular nucleotides into bioactive nucleoside 
intermediates (133, 156). Surface-bound CD73 converts adenosine 
monophosphate (AMP) to adenosine, which, when released, can activate 
several transmembrane adenosine receptors or can be internalized through 
dipyridamole-sensitive carriers (30, 131). Extracellular Adenosine 
Triphosphate (ATP) liberated during hypoxia and inflammation can either 
signal directly on purinergic receptors or can activate adenosine receptors 
following phosphohydrolysis to adenosine (35, 36). A number of studies 
indicated that CD73 is hypoxia-responsive through transcriptional induction 
and is associated with tissue protection in a variety of physiological settings 
(32, 85).  
In situations characerized by ATP hypercatabolism such as hypoxia, CD73 is 
implicated, because AMP, produced from ATP release in the extracellular 
medium, must be converted into adenosine before reuptake (81, 134). 
Therefore CD73 plays an important role in the defense against hypoxia, 
particularly in the intravascular space. Surface CD73 likely represents a 
protective pathway for the maintenance of barrier function in epithelia and 
vascular endothelia. A HIF-1 binding site in the CD73 gene promoter was 
identified and different approaches defined a role of HIF-1 in the induction of 
CD73 (133). 
 
3.6.2 VEGF 
Vascular endothelial growth factor (VEGF) is a prime regulator of angiogenesis 
(24). VEGF is expressed in most types of human cancer, and increased 
expression in tumors is often associated with a less favorable prognosis. 
Induction of or an increase in VEGF expression can be caused by numerous 
environmental factors such as hypoxia (106, 123), mediated through the 
hypoxia-inducible transcription factors 1α and 2α (70). The binding of VEGF 
leads to a cascade of different signaling pathways (122), resulting in the up-
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regulation of genes involved in mediating the proliferation and migration of 
endothelial cells and promoting their survival and vascular permeability (70). In 
vivo VEGF induces angiogenesis as well as permeabilization of blood vessels 
and plays a central role in the regulation of vasculogenesis (97).  
Thus, HIF-1 plays a critical role in angiogenesis by regulating the expression of 
the key angiogenetic factor: VEGF.  
 
3.6.3 FN-1 
Important properties of invasive cancer cells include decreased cell-cell 
adhesion, cytoskeletal remodeling, increased mortility, increased production of 
extracellular matrix (ECM) proteases, and syntehsis of new ECM components 
(76). Fibronectin-1 (FN-1) is one of the major ECM proteins associated with 
tumor invasion (23, 61). Krishnamachary et al. showed that hypoxia or HIF-1α 
overexpression stimulates matrigel invasion and that FN-1 mRNA expression 
is induced by hypoxia in wild-type embryonic stem (ES) cells but not in HIF-1α-
null cells (76).  
 
3.6.4 COX 2 
Cyclooxygenase (COX)-2 is the inducible key enzyme for prostanoid 
biosynthesis. COX-2, like its isoenzyme COX-1, catalyses the conversion of 
arachidonic acid to endoperoxide intermediates, which are ultimately 
converted to prostanoids. It is overexpressed in most colorectal carcinomas 
and a subset of adenomas (29, 33), and accumulating evidence supports an 
important role for COX-2 in colorectal tumorigenesis (15). Whereas COX-1 is 
expressed constitutively in most tissues and appears to be responsible for 
housekeeping functions, COX-2 is transcriptionally induced and thought to be 
the isoform responsible for the production of pro-inflammatory prostanoids that 
play a central role in regulation of inflammation (64). Analyses reveal that 
COX-2 up-regulation is associated with HIF-1α induction (65). 
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3.7 Respiratory syncytial virus 
Respiratory syncytial virus (RSV) is the major cause of serious lower 
respiratory disease in infancy and early childhood (42) and worldwide the most 
frequent cause of bronchiolitis and pneumonia in infants requiring 
hospitalization (3). Bronchiolitis, the more severe clinical manifestation of RSV 
infection, is characterized by necrosis and sloughing of the respiratory 
epithelium and plugging of the small bronchioles with fibrin and mucus (2, 28). 
These infections can be associated with serious morbidity and mortality, 
especially in children less than six years of age and children with comorbid 
chronic illnesses (82). Infants with congenital heart disease infected with RSV 
can have a significantly more severe illness and a higher mortality rate than 
other children (87). Thus, RSV is one of the most common and troublesome 
viruses of infancy (102). RSV is also a significant contributor to illness in adult 
populations especially in the elderly (39) and is recognized to be a major 
nosocomial hazard, especially in high-risk patients (51).  
 
RSV is an enveloped single-stranded negative-sense RNA virus of the 
Paramyxoviridae family (52). Closely related viruses include parainfluenza 
virus, measles and mumps (17). The genome of the virus is composed of a 
single strand of ribonucleic acid (RNA) containing only 10 genes. A total of 11 
proteins are encoded within this RNA genome. Nine of these are structural 
proteins and surface glycoproteins that form the viral coat and bring about 
attachment of the virus to the host cell. The remaining two direct the replication 
process of the virus once it infects its host cell (12).  
 
Recent molecular studies of RSV identified two envelope glycoproteins – 
protein G and protein F - of RSV as the major viral antigens. Of the 11 viral 
proteins encoded by the RSV genome, only the F and G glycoproteins were 
found to induce neutralizing antibodies. The fusion glycoprotein (protein F) 
appears to be important for inducing protective immunity and is associated 
with T helper subset 1 cytokine expression (79, 136). It mediates viral 
penetration by fusion of the viral envelope to the host cell membrane, resulting 
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in penetration of the viral RNA into the cell and also mediates cell-cell spread 
via membrane fusion (60, 99, 146). In this way, a characteristic fusion of 
human cells in tissue cultures known as the syncytial effect is released (71).  
The major glycoprotein G seems to be the viral attachment protein and 
appears to be linked to pathogenesis of RSV disease (99).  
 
Two subtypes of RSV, A and B, have been identified. Subtype B is 
characterized as the asymptomatic strain of the virus that the majority of the 
population experiences. The more severe clinical illnesses involve Subtype A 
strain which tends to predominate in most outbreaks (5).  
 
RSV is a ubiquitous pathogen in all human populations and is transmitted 
through close contact with a person who has an active infection or direct 
contact with infectious secretions or environmental surfaces. The incubation 
period is 2-8 days after initial contact, with the most likely period being 4-6 
days. An RSV infection does not produce substantial immunity to subsequent 
infection; thus, reinfections are common (12).  
 
The epithelium of the respiratory mucosa, which main function is to provide a 
protective physical barrier against injurious inhaled stimuli, is the main target of 
RSV. Following inhalation or self-inoculation of the virus into the nasal mucosa 
and infection of the local respiratory epithelium, RSV spreading along the 
respiratory tract occurs mainly by cell-to-cell transfer of the virus (53). Infection 
of respiratory epithelial cells is the first event occurring after RSV inhalation or 
inoculation. This is rapidly followed by the induction of a network of epithelial 
cell gene products and a number of molecules are produced by human 
epithelial cells as a consequence of RSV infection. Among them are potent 
immunomodulatory and inflammatory mediators (47, 112).  
In acute bronchiolitis the main lesion is epithelial necrosis when a dense plug 
is formed in the bronchiolar lumen leading to trapping air and other mechanical 
interference with ventilation: in interstitial pneumonia, there is widespread 
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inflammation and necrosis of lung parenchyma, and severe lesions of the 
bronchial and bronchiolar mucosa as well (2).  
As such, RSV is characterized by a particularly prominent inflammation of the 
pulmonary mucosa - both in natural and experimental infections (42, 137). In 
fact, RSV is among the most potent biological stimuli that induce the 
expression of inflammatory genes, including those encoding chemokines. 
Studies on mechanisms that control virus-mediated airway inflammation are 
currently areas of intense investigation (46-50).  
 
To examine the immunopathogenesis of RSV infection – during both the acute 
and chronic phases of the disease – and to study the dynamics of RSV 
replication, a mouse model of RSV infection was developed by Mejías et al. 
(92). Using this model, they showed that RSV induces significant inflammatory 
changes in the lungs which evolve into a chronic phase characterized by 
persistant airway inflammation and airway hyperresponsiveness, even when 
the virus is no longer detectable by quantitative culutures. These findings 
support previous observational studies of children suggesting that RSV is 
associated with long term airway disease (124, 130). Children who recover 
from RSV bronchilitis are at increased risk of recurrent wheeze and a 
significantly higher rate of asthma is diagnosed in later childhood (102). With 
recent evidence that RSV can persist, it is possible that low-level viral 
replication might drive chronic inflammation in some individuals with chronic 
lung diesease (101).  
 
Although it has been clearly shown that the development of a specific immune 
response to RSV is partly responsible for injury to the lungs and RSV-induced 
diseases are mediated through active cytokines released during infection, the 
knowledge of the pathogenetic mechanisms of the RSV disease is still 
inadequate (101, 102). Severe RSV disease appear to be associated with a 
misdirected immune response, characterized by enhanced release of 
mediators and infiltration of a range of monocytes and polymorphonuclear cells 
(40, 71) but many aspects still remain understood poorly. 
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3.8 Problem description  
Previous studies have shown increased levels of HIF-1 during various 
infections. These include infections with different viruses like Epstein-Barr 
(144), Hepatitis B (55) or C (96), bacteria (10, 25, 105, 158) and parasites (4).  
 
However, none of these studies has used RSV as etiologic agent. As 
discussed in section 3.7, RSV represents a significant hazard, especially to 
high-risk patients and young children. To explore new therapeutical options, it 
would be beneficial to know about the interdependencies between RSV 
infection and HIF-1 stabilization.  
 
Therefore, we have chosen to explore HIF-1 activation and gene-transcription 
during RSV infection. Beyond that, we have investigated the mechanism used 
by RSV to induce the HIF-1 pathway.  
 
We hypothesized a role of HIF-1 as transcriptional regulator during infections 
with respiratory syncytial virus and pursued HIF-1 activation and gene-
transcription during RSV infection. 
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4 Materials 
This section lists the materials and equipment used in the experiments 
executed for the on-hand study.  
 
 
Equipment 
Centrifuge 5417R (Eppedorf, Hamburg, Germany) 
Confocal laser scanning Microscope (Leica, Bensheim, Germany).  
Electrophorese Unit (Invitrogen, Karlsruhe, Germany) 
Hypoxia Chamber (InvivO2 400) (Ruskinn Technology Limited, Leeds, UK) 
iCycler (Bio-Rad Laboratories Inc., Hercules, California, USA) 
Incubator Cytoperm2 (Heraeus, Hanau, Germany) 
i-STAT Analyzer (Abbott, Wiesbaden, Germany) 
Magellan-Reader (Tecan, Crailsheim, Germany)  
Megafuge 1.0R (Heraeus, Hanau, Germany) 
Microscope (Leica, Bensheim, Germany) 
Photometer (Pharmacia, Freiburg, Germany) 
Pipetboy (Integra Bioscience, Fernwald, Germany) 
Pipetts (Eppendorf AG, Hamburg, Germany) 
Power Pac 3000/200 (Bio-Rad Laboratories Inc., Hercules, California, USA) 
Refrigerator -20°C (Linde, Siegen, Germany) 
Refrigerator -80°C (Labotec, Göttingen, Germany) 
Rotator (neoLab, Heidelberg, Germany) 
Shaker (Janke&Kunkel IKA-Labortechnik, Staufen, Germany)  
Speci-Mix (Bioblock Scientific, Illkirch Cedex, France) 
Table Centrifuge (Carl Roth GmbH&Co. KG, Karlsruhe, Germany) 
Thermomixer (Eppendorf AG, Hamburg, Germany) 
Trans Blot Cell Chamber (Bio-Rad, 
UV-Table (Biometra, Göttingen, Germany) 
Vortex-Genie2 (Scientific Industries Inc., Bohemia, NY, USA) 
Water bath (GFL, Burgwedel, Germany) 
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Weighing machine (Ohaus, Pine Brook, NJ, USA) 
 
Reagents 
Accutase (PAA Laboratories, Pasching, Austria) 
Albumin from bovine serum (Sigma-Aldrich, Steinheim, Germany) 
Ammoniumpersulfat (Bio-Rad, Hercules, California, USA) 
Antibiotic-Antimycotic-Solution (Sigma-Aldrich, Steinheim, Germany) 
Bromphenolblau (AppliChem GmbH, Darmstadt, Germany) 
Di-Natriumhydrogenphosphat (AppliChem GmbH, Darmstadt, Germany) 
Destilled Water (Invitrogen, Karlsruhe, Germany) 
EDTA (Sigma-Aldrich, Steinheim, Germany) 
Ethanol (Merck, Darmstadt, Germany) 
F-12 HAM medium (Invitrogen, Karlsruhe, Germany)  
FCS (Invitrogen, Karlsruhe, Germany) 
Full range Rainbow RPN800V (Amersham, Buckinghamshire, UK) 
Glycerol (Sigma-Aldrich, Steinheim, Germany) 
Hepes-KOH (Invitrogen, Karlsruhe, Germany) 
Igepal Electrophoresis Reagent, NP40 (Sigma-Aldrich, Steinheim, Germany) 
iQ-Sybr Green Supermix (Bio-Rad, Hercules, California, USA) 
Kaliumdihydrogenphosphat (Merck, Darmstadt, Germany)  
Kaliumchlorid (Merck, Darmstadt, Germany) 
L-Glutamin (Sigma-Aldrich, Steinheim, Germany) 
Magic Mark (Invitrogen, Karlsruhe, Germany) 
Methanol (Merck, Darmstadt, Germany) 
MgCl2  (Merck, Darmstadt, Germany) 
Natriumchlorid (Sigma-Aldrich, Steinheim, Germany) 
Nitrocellulose membrane (Bio-Rad Laboratories, Inc., München, Germany).  
Nonfat dried milk powder (AppliChem GmbH, Darmstadt, Germany) 
PBS minus (Invitrogen, Karlsruhe, Germany) 
PBS plus (Invitrogen, Karlsruhe, Germany) 
Perm/Wash-solution (PharMingen, BD-Bioscience, Heidelberg, Germany) 
ProLong Gold antifade reagent with DAPI (Invitrogen, Karlsruhe, Germany) 
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PVDF-Membrane (Bio-Rad Laboratories Inc., München,) 
Rainbow Marker(Amersham, Buckinghamshire, UK)  
Rotiphorese Gel 30 (Carl Roth GmbH+Co.KG, Karlsruhe, Germany) 
SDS (Sigma-Aldrich, Steinheim, Germany) 
Temed (Sigma-Aldrich, Steinheim, Germany) 
Tris-Base (AppliChem GmbH, Darmstadt, Germany) 
Tris/Glycin buffer (Bio-Rad Laboratories GmbH, München, Germany) 
Tris/Glycin/SDS buffer (Bio-Rad Laboratories GmbH, München, Germany) 
Tris-HCl (Merck, Darmstadt, Germany) 
Triton X 100 (Sigma-Aldrich, Steinheim, Germany) 
Trypan Blue Solution (0,4%) (Sigma-Aldrich, Steinheim, Germany) 
Tween-20 (Applichem, Darmstadt, Germany) 
Western Blot Stripping Buffer (Pierce, Bonn, Germany) 
Protease-Inhibitors: 
- Aprotinin (Appli-Chem, Darmstadt, Germany) 
- Leupeptin (Appli-Chem, Darmstadt, Germany) 
- Pepstatin (Boehringer, Mannheim, Germany) 
- PMSF (Appli-Chem, Darmstadt, Germany) 
- OV (Sigma-Aldrich, Steinheim, Germany) 
- DTT (Sigma-Aldrich, Steinheim, Germany) 
 
Kits 
BCATM Protein Assay Kit (Pierce, Bonn, Germany)  
Chemiluminescent Substrate Kit (Pierce, Bonn, Germany) 
Cytofix/Cytoperm (PharMingen, BD-Bioscience, Heidelberg, Germany) 
ELISA-Kit for human VEGF (R&D Systems, Minneapolis, MN, USA) 
RNA II Kit (Macherey & Nagel, Düren, Germany) 
iScript™cDNA Synthesis Kit (Bio-Rad, München, Germany) 
 
Materials 
Cell Scraper (Costar, NY, USA) 
Combs: 1,5mm; 15well (Invitrogen, Carlsbad, CA, USA) 
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Eppendorf Cups (Eppendorf AG, Hamburg, Germany) 
Eppendorf Tips (Eppendorf AG, Hamburg, Germany) 
Gel-Cassettes (Invitrogen, Karlsruhe, Germany) 
Glass Slides (NalgeNuc International, Naperville, IL, USA) 
Microtiter Plate 96 well (nuncTM, Brand Products, Denmark) 
Pipet 5ml/10ml/25ml (BD Bioscience, Erembodegem, Belgium) 
Syringe 1ml (Becton Dickinson, Le Pont De Claix, France) 
Tissue culture Dishes (Cellstar, Frickenhausen, Germany) 
Tissue culture Flasks 75cm2 (Techno Plastic Products AG, Trasadingen,  
Switzerland)  
Tissue culture Flasks 70ml (Becton Dickinson, Le Pont De Claix, France) 
Tubes 50ml/15ml (Becton Dickinson, Le Pont De Claix, France) 
 
Antibodies 
Anti-HIF-1α rabbit polyclonal IgG (upstate, Lake Placid, NY) 
Anti-HIF-1α mouse Mab (BD-Bioscience, Heidelberg, Germany 
Anti-RSV mouse IgG (Acris, Hiddenhausen, Germany) 
Alexa Fluor 488 goat anti-rabbit IgG (Invitrogen, Karlsruhe, Germany) 
Alexa Fluor 594 goat anti-mouse IgG (Invitrogen, Karlsruhe, Germany) 
Beta-Actin antibody (Cell Signaling, Danvers, MA) 
COX2 goat polyclonal IgG (Santa Cruz, Heidelberg, Germany) 
FN goat polyclonal IgG (Santa Cruz, Heidelberg, Germany) 
HRP-labelled secondary antibodies: 
- goat anti-rabbit 
- donkey anti-goat,  
- goat anti-mouse   (Santa Cruz, Heidelberg, Germany) 
 
Primers 
- CD 73  
- sense primer 5’-AAG GAA GGG GAA GAA CAG GA-3’  
- antisense primer 5’-GGC AGA GCT GAT GGA ATC TC-3’  
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- COX2   
- sense primer 5'-AAA CCT CAG CTC AGG ACT GC-3' 
- antisense primer 5'-GGC ACT AGC CTC TTT GCA TC-3'  
- FN1   
- sense primer 5’-AGG CTC AGC AAA TGG TTC AG-3’ 
- antisense primer 5’-TCG GCT TCC TCC ATA ACA A-3’ 
- Human beta-actin  
- sense primer, 5'-GGT GGC TTT TAG GAT GGC AAG-3' 
- antisense primer, 5'-ACT GGA ACG GTG AAG GTG ACA G-3' 
- VEGF  
- sense primer 5’-TTG CCT TGC TGC TCT ACC TC-3’  
- antisense primer 5’-AGC TGC GCT GAT AGA CAT CC-3’ 
- HIF-1α 
 - sense primer 5’-ACC TCG CTG ACC AGT TAT GAT TGT GAT CAA  
GAG TCA CAA TCA TAA CTG GTC AGC TT-3’  
- antisense primer 5’-CAA AAA GCT GAC CAG TTA TGA TTG TGA  
CTC TTG ATC ACA ATC ATA ACT GGT CAG CG-3’  
 
Cells 
A549 cells (American Type Culture Collection, Wesel, Germany)  
 
Buffer 
RIPA-Buffer 
 1mM Tris-HCl 
 250mM NaCl 
 1mM EDTA 
 Triton X 100 1% 
 NP40 1x Igepal Electrophoresis Reagent  
 Materials 
 
 
 
31 
Transfer buffer:  
200ml 10x Tris/Glycin buffer 
 400ml Methanol 
 1400ml Aqua dest. 
 
Running buffer:  
200ml 10x Tris/Glycin/SDS buffer  
 1800ml Aqua dest.  
 
Nuclear Proteins:  
  - Buffer A:   
10 mM Hepes-KOH, pH 7.9 
1.5 mM MgCl2 
10 mM KCl 
0.5 mM Dithiothreitol (DTT)  
0.2 mM Phenylmethylsulfonyl fluoride (PMSF) 
 
  - Buffer B:   
20 mM Hepes-KOH, pH 7.9 
25% Glycerol 
420 mM NaCl 
1.5 mM MgCl2 
0.2 mM EDTA 
0.5 mM DTT 
0.2 mM PMSF 
 
  - Buffer C   
20 mM Hepes-KOH, pH 7.9 
25% Glycerol 
420 mM NaCl 
1.5 mM MgCl2 
0.2 mM EDTA 
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0.5 mM DTT 
0.2 mM PMSF 
2 mM Benzamidine 
5 mg/ml Leupeptin 
 
Upper-Buffer for SDS Page, pH 6,8 
 30,3g Tris-Base (0,5M)  
 2g SDS (0,4%) 
 500ml Aqua dest.  
 
Lower-Buffer for SDS Page, pH 8,8 
 90,85 Tris-Base (1,5M) 
 2g SDS (0,4%) 
 500ml Aqua dest.  
 
Lämmli 4x non-reducing 
 2,5ml TrisHCl 1M ph 6,8 
 4,0 ml Glycerol 
 0,8g SDS 
 0,01g Bromphenolblau 
 1ml Aqua dest.  
 
TBS 10x, pH 7,6 
 24,2g Tris-Base 
 80g NaCl 
 in 1l Aqua dest. 
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PBS 10x, pH 7,2-7,4 
 8g NaCl (137mM)  
 0,2g KCl (2,7mM) 
 1,44g Na2HPO4 (8,1mM) 
 0,2g KH2PO4 (1,5mM) 
 in 1l Aqua dest.  
 
Software 
Microsoft Excel, Microsoft Office Professional Edition 2003 
Microsoft Word, Micorsoft Office Professional Edition 2003 
GraphPad Software, Prism 4 for Windows Version 4.03 
JMP statistical software (SAS Institute Inc.) 
EndNote 8, Thomson Reuters 
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5 Methods 
The following sections describe the experiments executed for this study, 
including cell culture, infection with RSV and subsequent testings with samples 
extracted from infected cells.  
Other sections describe the immunohistochemical staining, blood gas analysis 
and experiments with cells following siRNA repression of HIF-1.  
 
We also describe the setup for the in vivo experiments. The mice were housed 
and infected at the animal research facility of the University Texas Medical 
Branch (UTMB), Galveston, Texas. While the extraction of lung nuclear 
proteins was also performed there, the protein analyses were conducted in the 
context of the on hand thesis (Department of Anaesthesiology and Intensive 
Care Medicine, University of Tuebingen, Tuebingen, Germany).  
 
The last section is dedicated to the statistical analysis that have been 
performed.  
 
5.1 Culture of epithelial cells  
A549 cells (American Type Culture Collection, Wesel, Germany) were cultured 
as described previously (46). In short, A549 were grown in F-12 HAM medium 
(Invitrogen, Karlsruhe, Germany) supplemented with 10% fetal bovine serum 
(Invitrogen, Karlsruhe, Germany) and 1% Antibiotic-Antimycotic-Solution 
(Sigma-Aldrich, Steinheim, Germany). L-Glutamin was adjusted to a total 
quantity of 2mM.  
 
The cells were maintained under standard-conditions of 37°C in 20% O2 and 
5% CO2 and subcultivated with a ratio of 1:3 to 1:5 two to three times per 
week.  
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5.2 Infection with RSV 
Human RSV was purified by polyethylene glycol precipitation, followed by 
centrifugation on 35 to 65% discontinuous sucrose gradients as described 
previously (100, 139). The virus divided into aliquots and stored at -80°C until 
use. Virus titers were determined by a methylcellulose plaque assay (73).  
For experiments with inactivated RSV, the virus was exposed to an UV light 
source for 20 minutes as described previously for the inactivation of RSV 
(100).  
A549 cells were infected when they reached 70-80% confluence, using 
different multiplicities of infection (MOI). The virus was added immediately after 
removal of the culture medium in a small amount of serum-free medium for  
1 h. Additional media was added and the infection was continued for indicated 
time periods (46). 
 
5.3 Protein extraction 
Supernatants were discarded and 200µl Lysis-Buffer (1mM Tris-HCl, 250mM 
NaCl, 1mM EDTA, Triton X 100 1%, NP40 1x Igepal Electrophoresis Reagent, 
Aprotinin 1µg/ml, Leupeptin 1µg/ml, Pepstatin 1µg/ml, PMSF 1mM and OV 
1mM) was added. After scraping and collecting into tubes, the cell-lysate was 
incubated at 4°C for 20 minutes on a rotator. Cell debris was removed by 
centrifugation at 13000g for 15 minutes and discharged.  
Protein concentrations were determined using the BCATM Protein Assay Kit 
(Pierce, Bonn, Germany) according to the manufacturer’s instructions. 
 
5.4 Nuclear protein extraction 
Nuclear Proteins were isolated from A549 cells using a modification of 
methods previously described (14).  
In short, cells were lysed in 500µl cold buffer A (10 mM Hepes-KOH, pH 7.9, 
1.5 mM MgCl2, 10 mM KCl, 0.5 mM Dithiothreitol (DTT), 0.2 mM 
phenylmethylsulfonyl fluoride (PMSF)), scraped and collected into tubes and 
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incubated for 15 min on ice. After adding 7,5µl solution containing 10% NP40, 
vortexing for 30 seconds and incubation for three minutes on ice, the tubes 
were centrifuged for 2 minutes at 6000g at 4°C. The cytoplasmic proteins in 
the supernatant were collected and flash-frozen. Next, the pellet was 
resuspended in 100µl of cold buffer B (20 mM Hepes-KOH, pH 7.9, 25% 
glycerol, 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM DTT, 0.2 mM 
PMSF). After centrifugation (12000g at 4°C for 30 minutes), the supernatant 
was discarded and the pellet was resuspended in 50µl of buffer C (25% 
glycerol, 20 mM Hepes-KOH, pH 7.9, 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM 
EDTA, 0.5 mM DTT, 0.2 mM PMSF, 2 mM benzamidine, 5 mg/ml leupeptin) 
and incubated for 45 minutes at 4°C. Cellular debris was removed by 5 
minutes of centrifugation (6000g at 4°C) and the supernatant was flash-frozen 
at -80°C.  
 
Protein concentrations were determined using the BCATM protein assay kit 
(Pierce, Bonn, Germany) as instructed by the manufacturer. 
 
5.5 Western blotting 
Proteins were diluted in radio-immuno precipitation assay (RIPA) buffer to 
equivalent protein concentrations. After adding 4x Laemmli sample buffer they 
were immediately heated for 10 minutes at 70°C, separated on a 12% 
polyacrylamide gel and transferred to a nitrocellulose membrane 
(Polyvinylidene Difluoride, Bio-Rad Laboratories, Inc., München, Germany). 
Rainbow (Amersham, Buckinghamshire, UK) and MagicMark (Invitrogen, 
Karlsruhe, Germany) were used for size analysis and blotting control. The 
membranes were blocked overnight at 4°C in TBS containing 0,05% Tween 
and supplemented with 3% BSA and 3% skimmed milk.  
The membranes were then incubated in 1:500 COX2 goat polyclonal IgG 
(Santa Cruz, Heidelberg, Germany) or 1:500 anti RSV mouse IgG (Acris, 
Hiddenhausen, Germany) or 1:500 FN goat polyclonal IgG (Santa Cruz, 
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Heidelberg, Germany) or 1:1000 beta-Actin antibody (Cell Signaling, Danvers, 
MA) in blocking buffer.  
After three washes, membranes were incubated with horse-radish-peroxidase 
(HRP)-labelled secondary antibodies (goat anti-rabbit or donkey anti-goat or 
goat anti-mouse 1:1000; Santa Cruz, Heidelberg, Germany) for 45 minutes at 
room temperature. The wash was repeated and proteins were detected by 
enhanced chemiluminescence, using the Chemiluminescent Substrate Kit 
(Pierce, Bonn, Germany).  
Western immunoblotting for HIF1-alpha was performed using 1:500 Anti-HIF-
1α rabbit polyclonal IgG (upstate, Lake Placid, NY) following the 
manufacturers protocol without the use of Tween.  
 
5.6 Enzyme-linked immunosorbent assay (ELISA) for 
determination of chemokines 
Total protein samples of infected or non-infected A549 cells were tested for 
VEGF by use of a commercial ELISA kit (R&D Systems, Minneapolis, MN, 
USA) as instructed by the manufacturer.  
In short, samples were added to a 96 well microtiter plate, which was coated 
with murine monoclonal antibody to VEGF. The unbound protein was removed 
by washing and an enzyme linked polyclonal antibody specific to VEGF was 
added. After additional washing, substrate solution was added and incubated 
for 20 min. The color-reaction was stopped with stop solution and the amount 
of VEGF was determined by optical density of the samples by comparing the 
standards at 450 nm using an ELISA reader. 
 
5.7 Immunohistochemistry 
A549-cells were cultured on glass slides (NalgeNuc International, Naperville, 
IL) and infected with RSV at a MOI of 3.  
After 24 hours, they were fixed and permeabilized for immunofluorescent 
staining using Cytofix/Cytoperm (PharMingen, BD-Bioscience, Heidelberg, 
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Germany). After two washes with Perm/Wash-solution (PharMingen, BD-
Bioscience, Heidelberg, Germany) the slides were blocked for 30 minutes with 
5% skimmed milk in Perm/Wash-solution. Purified mouse anti-HIF1α Mab (BD 
Transduction Laboratories, BD-Bioscience, Heidelberg, Germany) and anti-
RSV mouse IgG (Acris, Hiddenhausen, Germany) were diluted 1:100 in 
Perm/Wash-solution and the slides were incubated for 30 minutes. Normal 
mouse and normal rabbit control IgG in a dilution of 1:200 were used.  
After two washes with Perm/Wash-solution, the slides were incubated for 30 
minutes with the secondary antibodies (Alexa Fluor 488 goat anti-rabbit IgG 
and Alexa Fluor 594 goat anti-mouse IgG, Invitrogen, Karlsruhe, Germany) in 
Perm/Wash. The slides were embedded with a reagent containing DAPI 
(Invitrogen, Karlsruhe, Germany) for staining of the nuclei.  
Fluorescence was visualized with a confocal laser scanning microscope 
(Leica, Bensheim, Germany).  
 
5.8 Reverse Transcription Polymerase Chain Reaction Analysis 
Realtime RT-PCR (iCycler; Bio-Rad Laboratories Inc., Hercules, California, 
USA), was used to verify COX2, FN-1, VEGF and CD73 transcript levels of 
RSV-infected A549 cells. After infection with RSV with an infection dose of 
MOI3 for 24h, total RNA was isolated using the RNA II Kit (Macherey & Nagel, 
Düren, Germany) and real-time RT-PCR was performed as described 
previously.  
The PCR reaction contained 10 pM for each of the following primers:  
Sense primer 5'-AAA CCT CAG CTC AGG ACT GC-3' and the antisense 
primer 5'-GGC ACT AGC CTC TTT GCA TC-3' for COX2.  
Sense primer 5’-AAG GAA GGG GAA GAA CAG GA-3’ and the antisense 
primer 5’-GGC AGA GCT GAT GGA ATC TC-3’ for CD73.  
Sense primer 5’-TTG CCT TGC TGC TCT ACC TC-3’ and the antisense 
primer 5’-AGC TGC GCT GAT AGA CAT CC-3’ for VEGF.  
Sense primer 5’-AGG CTC AGC AAA TGG TTC AG-3’ and the antisense 
primer 5’-TCG GCT TCC TCC ATA ACA A-3’ for FN1.  
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The primer set for COX2, FN1 and VEGF was amplified using increasing 
numbers of cycles of 95°C for 15 sec, 58°C for 30 sec, 72°C for 10 sec, and a 
final extension of 72°C for 1 minute. The primer set for CD73 was amplified 
using increasing numbers of cycles of 95°C for 15 sec, 60°C for 30 sec, 72°C 
for 10sec, and a final extension of 72°C for 1 minute. Human beta-actin (sense 
primer, 5'-GGT GGC TTT TAG GAT GGC AAG-3'; and antisense primer, 5'-
ACT GGA ACG GTG AAG GTG ACA G-3') was used as control. 
 
5.9 Stable repression of HIF-1α by siRNA 
Repression of HIF-1alpha by siRNA was achieved based on a modification of 
methods previously described (34, 56, 75, 78, 94). In short, a haripin primer 
with the sequence 5’-ACCTCGCTGACCAGTTATGATTGTGATCAAGAGTCA-
CAATCATAACTGGTCAGCTT-3’ and 5’-CAAAAAGCTGACCAGTTATGA-
TTGTGACTCTTGATCACAATCATAACTGGTCAGCG-3’ corresponding to 
position 2666-2685 of the HIF1α gene was selected. A549-cells were 
transfected using electroporation, followed by selection with G418 (1mg/ml). 
The control cell line was transfected with a non-specific control psiRNA-hH1 
neoscr plasmid.  
 
5.10  Blood Gas Analysis 
Blood gas analysis was performed to assess oxygen partial pressure in 
supernatants of uninfected or infected A549 cells. The cells were cultured and 
infected at a MOI of 1 or 5. One hour after infection the cell-culture flasks were 
filled up with serum free media and were sealed gas-tight. Analysis of the 
supernatants was performed immediately after removal via the I-STAT 
Analyzer (Abbott, Wiesbaden, Germany) at different time points as described 
previously (31, 56). 
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5.11  Infection of mice with RSV and extraction of lung nuclear 
proteins 
Female, 6- to 8-week-old BALB/c mice were purchased from Harlan (Houston, 
Texas, USA) and were housed in pathogen-free conditions in the animal 
research facility of the University Texas Medical Branch (UTMB), Galveston, 
Texas, in accordance with the National Institutes of Health and UTMB 
institutional guidelines for animal care. The Institutional Animal Care and Use 
Committee approved this protocol. Cages, bedding, food, and water were 
sterilized before use.  
 
Under light anesthesia, female, 6-8 weeks old BALB/c mice were infected 
intranasally with RSV at 1 x 107 plaque-forming units (PFUs), diluted in sterile 
phosphate-buffered saline (PBS) for a total inoculation volume of 50 µl, as 
previously described (47). As mock treatment, control mice were inoculated in 
the same way with an equivalent volume of sucrose diluted in D-PBS (21).  
At the indicated time points after infection (12, 24, and 48h) mice were 
anesthetized with an intraperitoneal injection of ketamine and xylazine before 
the thoracic cavity was opened (47). Lungs were then removed, quick frozen in 
liquid nitrogen and stored at -80°C until nuclear protein was isolated.  
 
Nuclear proteins were isolated from the lung tissue using a modified method 
described by Bohrer and colleagues (14). Lung tissue was homogenized in 5 
ml ice-cold Buffer A (10 mM 2-hydroxyethyl-piperazine N'-2-ethanesulfonic acid 
[Hepes]–KOH, pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM dithiothreitol [DTT], 
0.2 mM phemylmethyl sulfonyl fluoride [PMSF], 0.6% nonident P40 [NP-40]) 
and centrifuged at 350 x g, 4°C for 30 seconds. The supernatant was kept on 
ice for 5 minutes and centrifuged for 5 minutes at 6,000 x g at 4°C, and the 
pellet was resuspended in 200 µl Buffer B (10 mM Hepes–KOH, pH 7.9, 1.5 
mM MgCl2, 10 mM KCl, 1.2 M sucrose, 0.5 mM DTT, 0.2 mM PMSF). After 
centrifugation (13,000 x g, 4°C, 30 minutes), the pellet was resuspended in 100 
µl Buffer C (20 mM Hepes–KOH, pH 7.9, 1.5 mM MgCl2, 420 mM NaCl, 0.2 
mM ethylenediamine-tetraacetic acid, 0.5 mM DTT, 0.2 mM PMSF, 2 mM 
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benzamidine, 5 µg/ml leupeptin, 25% glycerol), incubated on ice for 20 
minutes, and centrifuged (6,000 x g, 4°C, 2 minutes). The supernatant was 
quick frozen in aliquots at –80°C. 
 
Housing and infection of the mice as well as lung nuclear protein extraction 
took place in the animal research facility of the University Texas Medical 
Branch (UTMB), Galveston, Texas. 
 
HIF-1α stabilization was determined by Western blot analysis as described 
previously (94). The protein analyses were conducted in the context of the on 
hand thesis in the department of Anaesthesiology and Intensive Care Medicine 
in Tuebingen. 
 
5.12  Statistical Analysis 
Data collection and statistical analysis was performed using Microsoft Excel 
(Microsoft Office Professional Edition 2003) and Graph Pad Prism (GraphPad 
Software Inc., Prism 4 for Windows Version 4.03) as well as JMP statistical 
software (SAS Institute Inc.). 
All presented values were calculated from at least three separate experiments.  
 
For the analysis of the data of Figure 2 C, 3, 4, 5 C-D and 6 A-D we used an 
analysis of variance with the fixed factor goups and the random factor number 
of experiment. The ratios of HIF-1α with respect to β-Actin were transformed to 
logarithms in order to stabilize the variances.  
 
For the analysis of the data of Fig. 5B and 8B we used an analysis of variance 
with the fixed factor goups and time together with their interaction and the 
random factor number of experiment 
 
The geometric means of the ratios are given together with their 95% 
confidence intervals. 
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For the analysis of the data in Fig 7A we fitted the following nonlinear model by 
the method of least squares to the data: 
b1 + b0 − b1( )exp −αt( ), 
where b1 is the asymptotic pO2, b0 is the initial pO2 and α  is the rate at which 
the initial pO2 approaches the asymptotic pO2 as a function of time t. We 
provide the parameter estimates together with their 95% confidence intervals. 
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6 Results 
This chapter presents the results from the study.  
Each section is structured to first explain a result and the experiment that 
delivered it, then show the associated figures and finally provide a figure 
legend. This system is followed for seven result-sections, including eight 
figures. 
 
As first step, immunohistochemical staining for immunolocalization of HIF-1α 
during RSV infection in pulmonary epithelial cells was performed wherein RSV 
infected cells stained positive for HIF-1α. Western blot analysis confirmed 
these results and demonstrate HIF-1α protein stabilization during RSV 
infection. To pursued functional consequences, we measured transcription 
levels and showed an induction of known HIF-1 target genes following RSV 
infection. HIF-1α loss-of-function studies revealed significant induction of the 
tested HIF-1-target genes in control cells, while these responses were 
abolished in HIF-1 -/- cells. Investigating the effects of UV-inactivation, we 
showed that only functional RSV virus is capable to cause HIF-1 stabilization 
and HIF-1-dependent gene induction. In Figure 7 we suggest oxygen 
independent stabilization of HIF-1α by measurements of oxygen partial 
pressures in the supernatants of RSV infeced cells.  
Finally, we used a mouse model to confirm our in vitro findings and showed 
that HIF-1α was stabilized during murine RSV pneumonia.  
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6.1 Immunolocalization of HIF-1α during RSV infection in vitro 
Recent evidence revealed that numerous parallels exist between inflammation 
and hypoxia, including changes in barrier function or inflammatory cell 
recruitment (37, 38, 67, 74, 75, 125, 126). In addition, recent studies have 
revealed that during infections with human pathogens HIF-1 is activated (56, 
69). Based on previous studies showing that RSV infections are characterized 
by a particularly prominent inflammation of the pulmonary mucosa - both in 
natural and experimental infections (42) and the fact that RSV is among the 
most potent biological stimuli that induce the expression of inflammatory 
genes, we hypothesized that HIF-1 is stabilized during infections with RSV and 
may contribute to RSV-associated changes in gene transcription. For our 
studies, we used A549 cells, a cell line derived from an alveolar cell carcinoma 
of the lung. As first step, we performed immunohistochemical staining with 
antibodies for RSV (green) or HIF-1α (red) using confocal laser scanning 
microscopy (Figure 1A). As counterstaining for the nuclei we used dapi 
staining (blue). As shown in Figure 1A, RSV infected cells also stained positive 
for HIF-1α, with localization of HIF-1α both in the cytosole and the nuclei. In 
contrast, uninfected A549 cells only had a very week signal for HIF-1α (Figure 
1B). Isotype controls and staining of infected A549 cells with secondary 
antibody alone were negative (data not shown). Taken together, these data 
reveal that during RSV infection, HIF-1α accumulates in the cytosole and the 
nucleus of infected pulmonary epithelia, suggesting HIF-1 activation during 
RSV infection in vitro. 
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Figure 1: HIF-1α during RSV infection of pulmonary epithelia. 
(A) ~1,5x105 A549-cells were seeded on glass slides and infected with RSV 
(multiplicity of infection, MOI 3). After 24h they were fixed, permeabilized and 
incubated with anti-HIF1α and anti-RSV IgG as primary antibodies. Alexa Fluor 
488 and Alexa Fluor 594 were used for staining. In addition, slides were 
counter-stained with Dapi. The cells were visualized with confocal laser 
scanning microscopy. Uninfected cells were used as controls (B). 
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6.2 HIF-1α protein is stabilized during RSV infection 
After having shown by confocal laser scanning microscopy that HIF-1α is 
stabilized during RSV infection, we next used Western blot analysis to confirm 
these results with a more quantitative approach. Here, we first confirmed 
successful infection of A549 cells using different infection doses (MOI1-5). As 
shown in Figure 2A, we found a close correlation of virus load with RSV G-
protein after 24h of infection (Figure 2A). In contrast, RSV pre-exposed to UV 
light source as previously described for RSV inactivation (100) showed no 
signal for intracellular RSV G-protein. Uninfected cells were used as negative 
control. As next step, we measured HIF-1α during RSV infection by Western 
blot analysis. These studies revealed an 7,15-fold increase in HIF-1α protein 
compared to non-infected A549 cells (Figure 2B and C, relative to beta-actin, 
MOI of 3). Interestingly, this HIF-response was completely attenuated when 
using UV-treated RSV virus (0,84-fold HIF-1α protein relative to beta-actin, 
Figure 2 B and C). In additional control studies, we exposed A549 cells to 
ambient hypoxia (2% oxygen over 24h), which was associated with a robust 
increase in HIF-1α protein (5,70-fold increase in HIF-1α). Taken together, 
these studies reveal robust stabilization of HIF-1α during infection with life 
RSV in vitro.
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Figure 2: HIF-1α protein measurements during RSV infection in 
vitro.  
(A, B) Cultured pulmonary epithelia (A549) were grown to 80% confluency, 
infected with intact (multiplicity of infection, MOI 1, 3 or 5) or UV-inactivated 
RSV (MOI 3). In other studies A549 cells were exposed over 24h to ambient 
hypoxia (2% oxygen). Cells were lysed and nuclear proteins were isolated, and 
Western immunoblotting for RSV G-protein (A) or HIF1α was performed. 
Uninfected cells were used as control (Co). The same blots were probed for   
β-actin expression as a control for protein loading. A representative blot of 3 is 
shown, in addition to densitometric analysis of HIF-1α protein levels relative to 
β-actin (C, n=3). The geometric means of the ratios are given together with 
their 95% confidence intervals. 
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6.3 HIF-dependent genes are induced following RSV infection 
After having demonstrated HIF-1α protein stabilization during infection with 
RSV, we next pursued functional consequences of HIF-1α in transcriptional 
gene induction during RSV infection. For this purpose, we performed 
expressional studies of known HIF-1-dependent genes during RSV infection. 
Thus, we measured transcript levels of CD73 (133), VEGF (86), Fibronectin1 
(FN1) (76) and COX2 (65) after 24h of RSV infection of A549 pulmonary 
epithelial cells using different RSV infection doses (MOI1-5). As shown in 
Figure 3, analysis of transcript levels by real-time RT-PCR revealed induction 
of all tested HIF-1 target genes. Extensions of these findings at the protein 
level by Western blot confirmed significant induction of COX2 or FN1 protein 
levels (Figure 4A and B). Similarly, measurements of VEGF in the 
supernatants from RSV infected pulmonary epithelial cells revealed 
significantly elevated levels of VEGF (Figure 4C). Taken together, these 
studies demonstrate induction of HIF-1-depedendent genes during RSV 
infection in vitro. 
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Figure 3: Transcript levels of HIF-1-dependent genes following RSV 
infection.  
Total RNA was isolated from RSV-infected (multiplicity of infection, MOI 1, 3 
and 5) or non-infected A549 cells (control) and (A) CD73, (B) VEGF, (C) FN1, 
(D) COX2 mRNA levels were determined by real-time RT-PCR. Data were 
calculated relative to internal housekeeping gene (β-actin) and are expressed 
as fold increase over uninfected control-cells at each infection dose. The 
geometric means of the ratios are given together with their 95% confidence 
intervals. 
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Figure 4: Protein levels of HIF-1-dependent genes following RSV 
infection.  
Total protein was isolated from RSV-infected (multiplicity of infection, MOI 1, 3 
and 5) or non-infected A549 cells. Protein levels were determined by Western 
blot and ELISA. The same blots were probed for β-actin expression as a 
control for protein loading. In addition, densitometric analysis of protein levels 
relative to β-actin were performed. Data are expressed as fold increase over 
uninfected control-cells at each infection dose. (A) COX2; (B) FN1 (C) VEGF. 
The geometric means of the ratios are given together with their 95% 
confidence intervals.  
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6.4 HIF-dependent gene expression during RSV infection in 
pulmonary epithelial cells following siRNA repression of 
HIF-1α 
To demonstrate a functional role of HIF-1 in the observed induction of HIF-
dependent genes induction during RSV infection, we next pursued HIF-1α-
loss-of-function studies. For this purpose, we generated a pulmonary epithelial 
cell line (A549 cells) with stable repression of HIF-1α. This was achieved via 
hairpin siRNA technique as we have done previously in other cell lines (34, 56, 
75, 78, 94). To demonstrate effective repression of HIF-1 in these cell lines, we 
utilized a model of ambient hypoxia. For this purpose, we exposed these cells 
to hypoxia over 24 or 48h (2% oxygen), while growth-synchronized control 
cells were maintained at room air (21% oxygen). These studies revealed 
significant accumulation of HIF-1α protein in control transfected cells in 
conjunction with attenuated HIF-1α stabilization in HIF-1α-siRNA-transfected 
A549 cells (Figure 5A and B). We utilized this model to directly test the 
functional role of HIF-1 in transcriptional modulation during RSV infection. 
Here, we measured transcript levels of control transfected or HIF-1α-targeted 
pulmonary epithelia. These studies revealed significant induction of HIF-1-
target genes (VEGF, CD73 or FN1) in control cells, while these responses 
were abolished in HIF-1α-targeted pulmonary epithelia. Taken together, these 
studies suggest a functional role of HIF-1α in transcriptional induction of HIF-1-
targeted genes during infection with RSV. 
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Figure 5: Transcript levels of HIF-dependent genes following  
HIF-1α siRNA repression during RSV infection.  
(A) HIF-1α protein levels in A549 cells following hairpin siRNA repression of 
HIF-1α (HIF-/-; A549 cells transfected with control siRNA:SCR). Cells were 
grown to 80% confluency and exposed to normoxia or hypoxia (2% oxygen) 
over indicated time period. Nuclear proteins were isolated and Western Blot 
analysis was performed for HIF-1α. The same blots were probed for β-actin 
expression as a control for protein loading. A representative blot of 3 is shown, 
in addition to densitometric analysis of HIF-1α protein levels relative to β-actin 
(B). (C, D, E) Total RNA was isolated from RSV-infected (multiplicity of 
infection, MOI 3) or non-infected A549 following HIF-1α repression (A549 HIF-
/-) or transfection with control siRNA (A549 scr). (C) VEGF, (D) CD73, (E) FN1 
transcript levels were determined by RT-PCR. Data were calculated relative to 
internal housekeeping gene (β-actin) and are expressed as fold increase over 
uninfected control-cells. The geometric means of the ratios are given together 
with their 95% confidence intervals.
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6.5 Influence of UV-inactivation of RSV on HIF-dependent gene 
induction 
In view of the above results, we hypothesized that only intact RSV is capable 
of HIF-1α stabilization and induction of HIF-1 target genes. Therefore, we next 
investigated the effects of UV-inactivated virus on the HIF-1α target genes. For 
this purpose, we measured VEGF, CD73, FN1 and COX2 transcript levels in 
A549 cells that were infected with intact or with UV-inactivated RSV (Figure 6 
A-D). Consistent with our studies above, we found significant induction of HIF-
1 target genes in RSV infected A549 cells. In contrast, induction of HIF-1 
target genes was completely abolished after similar infection doses with UV-
inactivated RSV. Taken together, these studies suggest that only functional 
RSV virus, capable of intracellular replication – is necessary to cause HIF-1-
dependent gene induction. 
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Figure 6: Transcript levels of HIF-dependent genes following 
infection with inactivated RSV.  
Total RNA was isolated from uninfected, RSV-infected or UV-inactivated RSV 
infected A549 cells. (A) VEGF, (B) CD73, (C) FN1, (D) COX2 transcript levels 
were determined by real-time RT-PCR. Data were calculated relative to 
internal housekeeping gene (β-actin) and are expressed as fold increase over 
uninfected control-cells at each infection dose. The geometric means of the 
ratios are given together with their 95% confidence intervals. 
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6.6 HIF-1α stabilization after RSV infection occurs independent of 
hypoxia  
Previous studies of infection and inflammation have revealed significant 
changes in metabolic supply and demand. For example, studies of murine 
colitis revealed convincing evidence that the mucosal surface is prone to 
inflammation-associated hypoxia (66, 67). Our above studies showed that 
intracellular uptake and binding of RSV appears to be necessary for HIF-1-
dependent gene induction. Therefore, we hypothesized that changes in 
metabolic supply and demand ratios during RSV infection may accompany 
RSF-infection and RSV-associated tissue hypoxia could lead to HIF-1 
activation. To address this hypothesis in an experimental setting, we measured 
oxygen partial pressures (pO2) values in the supernatants from RSV infected 
pulmonary epithelia or controls that were maintained in an oxygen 
impermeable culture system. As shown in Figure 7A, no differences in PO2 
values were observed between experimental groups. In fact, neither 
supernatant from control nor RSV-infected pulmonary epithelia showed 
significant degrees of hypoxia. Consistent with these findings, and as shown in 
Figure 7B, Western blot analysis confirmed that HIF-1α was not stabilized in 
control cells maintained under the above cell culture conditions. In contrast, we 
observed significant HIF-1α stabilization in RSV-infected pulmonary epithelia. 
Taken together, these studies suggest oxygen independent stabilization of 
HIF-1α during RSV infection.  
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Figure 7: Measurements of oxygen partial pressures (pO2) in the 
supernatants of RSV infected pulmonary epithelia.  
(A) A549 cells were cultured and infected at a multiplicity of infection (MOI) of 
1 or 5 in gas-tight sealed flasks. Oxygen partial pressure was measured in the 
supernatants at indicated time points following infection. (B) The same 
samples for were assessed for HIF-1α protein levels by Western blot. Blots 
were probed for β-actin expression as a control for protein loading. We provide 
the parameter estimates together with their 95% confidence intervals 
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6.7 HIF-1α is stabilized during murine RSV infection in vivo. 
As proof of principle for these concepts in vivo, we compared the influence of 
RSV infection on pulmonary HIF-1α stabilization using a previously described 
model (46-48, 50). This mouse model shows close similarity to the 
pathogenesis of RSV-induced lower airway disease in humans. In fact, recently 
established that the experimental infection of BALB/c mice with highly purified 
preparations of RSV A, at a dose of 107 PFU, induces a severe inflammatory 
response in lung tissue as early as 24 h after intranasal inoculation (47). Lung 
inflammation was characterized by an excess of monocytes/macrophages, 
lymphocytes, and to a lesser extent, neutrophils surrounding bronchioles and 
vessels, with evidence of the involvement of alveolar spaces (47). In the 
present studies, female BALB/c mice were inoculated intranasally with purified 
RSV. In control experiments, BALB/c mice matched in age, gender and weight 
were inoculated in the same way with an equivalent volume of vehicle. At the 
indicated time points after infection, mice were anesthetized, lungs were 
shockfrozen and HIF-1α was determined by Western blot analysis. As shown 
in Figure 8A and B, HIF-1α was stabilized with RSV infection at all 
measurement time points. Taken together, these data confirm our in vitro 
findings and suggest that during murine RSV pneumonia HIF-1α is stabilized. 
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Figure 8: HIF-1α protein during murine RSV pneumonia in vivo.  
Female, 4- to 6-week-old BALB/c mice were inoculated intranasally with 
purified RSV at 1 x 107 plaque-forming units (PFUs), diluted in sterile 
phosphate-buffered saline (PBS) for a total inoculation volume of 50 µl. As 
mock treatment, control mice were inoculated in the same way with an 
equivalent volume of sucrose diluted in D-PBS. Lungs were removed at 
indicated time-points, and HIF-1α protein levels were determined by Western 
blot analysis (A) or quantified by densitometry, relative to β-actin (B). The 
geometric means of the ratios are given together with their 95% confidence 
intervals.
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7 Discussion 
This chapter discusses the results described in the previous chapter and puts 
the findings in context with existing studies about the subject topic. While the 
general role of HIF-1 has been discussed extensively in previous studies, we 
are concentrating on HIF-1 in the context of inflammation and infection with 
RSV.  
 
We start by giving an overview of our findings. Then, the respiratory epithelium 
as primary target of RSV infection is discussed, followed by a section 
summarizing previous studies about HIF-1 during viral, bacterial and parasital 
infection. We elaborate on our findings about HIF-1 stabilization during RSV 
infection, and then discuss the mechanisms of HIF-1 stabilization during 
infection, particularly with regard to oxygen dependency.  
After a glance at other transcription factors, we finally question whether HIF-1 
stabilization during RSV infection might be protective or detrimental.  
 
7.1 General findings 
Many studies during the last decade have demonstrated a central role of HIF-1 
in mammalian oxygen homeostasis (120). HIF-1 activity is induced in a variety 
of cell types and, more recently many studies have also demonstrated a role of 
HIF-1 in the transcriptional coordination during inflammation and infection (56, 
69, 125, 157). In fact, previous studies have revealed that HIF-1 can be 
stabilized during infections with human pathogens via oxygen-dependent (69) 
or oxygen independent (56) pathways.  
 
In the present studies we pursued HIF-1α stabilization and gene-transcription 
during infection with RSV – one of the most potent biological stimuli to induce 
an inflammatory milieu (46-48, 50) and the major cause of serious lower 
respiratory tract infections in infancy and early childhood (42).  
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Initial studies of cultured pulmonary epithelia infected with RSV revealed 
stabilization of HIF-1 protein. Moreover, transcription of known HIF-1 target 
genes (VEGF, CD73, FN-1, COX-2) was induced following RSV infection while 
siRNA-dependent repression of HIF-1α abolished these responses. Induction 
of HIF-1 target genes was also completely abolished after infection with UV-
inactivated RSV. 
 
However, infection with RSV was not associated with increased oxygen 
consumption or cellular hypoxia, suggesting that HIF-1α stabilization and HIF-
dependent gene induction during RSV infection occurs in an oxygen-
independent fashion. Finally, studies of murine RSV pneumonia revealed 
significant HIF-1α stabilization throughout the course of the disease and 
suggest that RSV-associated HIF-1 activation also occurs in vivo.  
 
7.2 The respiratory epithelium 
In naturally acquired RSV infection, the primary target for viral replication is the 
respiratory epithelium (63). In bronchiolitis and pneumoniae, RSV antigen can 
be identified in epithelial cells from throughout the lower respiratory tract (20). 
Airway epithelial cells represent the principal initiators of pulmonary host 
defense mechanisms by their ability to synthesize and secret inflammatory 
mediators upon injury or infection. The immunomodulatory activity of the 
airway epithelium is of particular relevance to RSV infection, because RSV 
produces clinical disease through its replication within the airway mucosa (41).  
This replication is a process that alters epithelial cell chemokine expression, 
thereby inducing airway inflammation (22). The inflammatory response by 
infection of respiratory epithelial cells is an essential pathogenic component of 
RSV disease.  
 
An important role of the alveolar epithelium is to contribute to the 
alveolocapillary barrier, secret surfactant to lower the surface tension,  
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and clear edema (62). Epithelial cells are able to produce opsonins such as 
complement and surfactant proteins responsible for serum-independent 
phygocytosis of pathogens by neutrophils, monocytes, and macrophages (42). 
Therefore, respiratory epithelial cells appear to be ideally located and armed to 
function as initiators of host defense mechanisms by regulating the prototypic 
cellular elements of the innate immune system.  
A549 cells have proven to be excellent models of pulmonary type II epithelial 
cells for studying the production of several bioactive factors and the 
mechanisms of chemokine gene regulation (41, 63, 84, 129).  
In previous studies, HIF-1α induction was reported by acute hypoxia in A549 
cells (138).  
 
HIF-1 may contribute to multiple aspects of pulmonary pathophysiology in 
patients with chronic lung diesease (119). Immunohistolchemistry revealed 
expression of HIF-1α in most cell types within the hypoxic lung including 
bronchial epithelium and smooth muscle, alveolar epithelium and vascular 
endothelium (153). Reduced oxygen availability induces lung alveolar cell 
adaption through an activation of genes essential for cell survival mediated by 
HIF-1 (138).  
 
In this study we investigated the effects of acute RSV infection on pulmonary 
epithelial cells and revealed concomitant HIF-activation during RSV infection. 
 
7.3 HIF-1 during inflammation 
The hypoxia-inducible transcription factor (HIF)-1 is a major regulator of 
energy homeostasis and cellular adaption to low oxygen stress (157). The 
expression of HIF-1α plays an important role during inflammation and infection 
(105) as well as angiogenesis, tumor growth, invasion and metastasis (90). 
While hypoxia remains the undisputed ubiquitous inducer of HIF-1, other 
factors can also modulate increases in HIF-1α protein levels.  
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Activation of HIF-1α pathway during the life cycle of different pathogens has 
been the subject of increasing investigation, revealing a diversity of functional 
outcomes in disease progression. A variety of in vitro and in vivo functional 
assays of acute and chronic inflammation demonstrated a prominent role for 
the HIF-1α controlled pathway within inflamed tissues.  
 
7.3.1 HIF-1 during viral infections 
Previous studies have shown HIF-1 stabilization during infections with different 
viruses and local hypoxia was identified as a nonspecific host-cell defense 
against virus infection during the infection with vesicular stomatitis virus (VSV) 
(95). Epstein-Barr virus (EBV), a human herpesvirus that is associated with 
several types of malignancies, such as Burkitt’s lymphoma, lymphoproliferative 
disorders, T-cell lymphomas and Hodgkin’s disease, is reported to increase 
the expression of HIF-1α in different cell lines (144).  
Chronic infections with the hepatitis B and C viruses are epidemiologically 
associated with development of hepatocellular carcinoma. Hepatitis B virus 
(HBV) increases the protein level of HIF-1α by the direct interaction of HIF-1α 
under both normoxic and hypoxic conditions (55, 93). The cross-talk between 
a regulatory X protein (HBx) – one of the open reading frames encoded by the 
HBV genome – and HIF-1α was shown in (152). Furthermore, HBx enhanced 
transcriptional activity of HIF-1α in the reporter genes encoding hypoxia 
reponse element (152).  
Infection with hepatitis C virus, a single-stranded RNA virus also leads to  
stabilization of HIF-1α as reported in (96). 
In some cases, HIF-1α may help coordinate a host defense program to limit 
cell damage secondar to viral infection (157). 
 
7.3.2 HIF-1 during bacterial infections 
The effetiveness of innate immune defense against bacterial infections reflects 
a diverse array of highly specialized cellular functions. Biosynthesitic capacity, 
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metabolic activation and cytoskeletal rearrangements are required to effect 
microbial killing. Different observations argue for a pronounced dependence of 
neutrophils and macrophages on the known functions of HIF-1 (104).  
 
Increased levels of HIF-1α have been demonstrated during bacterial infection 
with a variety of bacterial species, including Streptococcus pyogenes, 
Streptococcus agalactiae, Staphylococcus aureus, Salmonella typhimurium 
and Pseudomonas aeruginosa (10, 25, 105, 158). These studies suggested 
that the HIF-1α response pathway is broadly adaptive in host defense (157).  
One clear demonstration of HIF-1α induction by a bacterial pathogen was 
provided in studies of Bartonella (B) henselae, a facultative intracellular 
bacterium and the causative agent of angiogenic proliferation of capillary 
vessels in bacillary angiomatosis. Infection with B henselae results in HIF-1 
activation in vitro and in vivo and leads to a gene expression pattern typical for 
the cellular response to hypoxia (69). The activation of HIF-1 was also 
investigated in a murine yersiniosis model. Infection with Yersinia (Y) 
enterocolica resulted in even more pronounced HIF-1 activation than during 
infection with B henselae (56).  
In other studies, a strain of the Gram-positive pathogen group A Streptooccus 
was chosen to provide evidence for increased HIF-1α expression following 
bacterial exposure. It was also found to represent a more potent stimulus for 
HIF-1α induction than hypoxia itself (105).  
 
7.3.3 HIF-1 during infections with parasites 
HIF-1α also appears to occur in the context of infection with protozoan 
parasites. Though much less well studied, HIF-1α is shown to be activated 
during different parasites infections.   
For example, cutaneous lesions can be generated in mice by infection with 
Leishmania amazonensis. HIF-1α induction in the cytoplasm and 
parasitophorous vacuoles of macrophages recruited to the microenvironmental 
can be clearly demonstrated in the later stages of infection (4).  
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Studies with Toxoplasma gondii and Trypanosoma cruza identified these 
obligate intracellular parasites as activators of HIF-1α induction (128).  
 
7.4 HIF-1 stabilization during RSV infection 
Lower respiratory tract infections caused by RSV are characterized by 
profound cellular inflammation of the airway mucosa, which contributes to 
disease manifestations, including air flow limitation, lung 
atelectasis/emphysema, and hypoxemia (111). The molecular mechanisms 
that regulate airway inflammation in viral respiratory infections are not fully 
understood and the in vivo signaling and transcriptional pathways that mediate 
airway mucosal inflammation in RSV infections are still largely unknown (50).  
It has previously been established that in airway epithelial cell lines a number 
of molecules are produced as a consequence of RSV infection. Among them 
are potent immunomodulatory and inflammatory mediators, including 
cytokines, chemokines, interferons and growth factors (42).  
Herein we show HIF-1 activation and gene-transcription during respiratory 
syncytial virus (RSV) infection.  
 
The requirement of infectious virus for the production of different chemotactic 
factors, for example the secretion of the proinflammatory C-C chemokines 
RANTES, MCP-1 and MIP-1α from epithelial cells was reported in previous 
studies (100). In other studies, the induction of nuclear-factor-IL6 (NF-IL6) was 
found to be strictly dependent on viral replication and could not be induced by 
UV-inactivated virus, demonstrating the requirement of viral replication for NF-
IL6 snythesis (63). However, UV-inactivation of RSV did not prevent virus-
induced EPO release or T-cell proliferation (27).  
 
Our above studies showed that intracellular uptake and replication of RSV 
appears to be necessary for HIF-1-dependent gene induction. We found 
significant induction of HIF-1 target genes in RSV infectes A549 cells but only 
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intact RSV appeared to be able to stabilize HIF-1alpha, whereas the HIF-
response was completely attenuated when using UV-treated RSV virus.  
 
7.5 Mechanisms of HIF-1 activation during infection 
Inflammatory responses are generally associated with significant changes in 
tissue metabolism. In particular, metabolic shifts during inflammation can result 
in significant tissue hypoxia with stabilization of HIF-1α and resultant induction 
of hypoxia-responsive genes. However, previous studies of HIF-1 during 
inflammation and infection have found oxygen-independent activation of HIF-1 
during infections with human pathogens.  
For example, a recent study on molecular mechanisms of how bacteria 
activate HIF-1 found a role of bacterial siderophores in HIF-1 activation during 
infection with Enterobacteriaceae (56). Here, the authors studied HIF-1 
activation and HIF-1-dependent gene induction in Peyer's patches that were 
analyzed after orogastric infection with Yersinia (Y) enterocolitica and 
orogastric Y enterocolitica infection in mice with a conditional deletion of HIF-
1α (66) in the intestine. These studies demonstrated that infection of mice with 
Y enterocolitica led to functional activation of HIF-1 in Peyer's patches. 
Moreover, mice with conditional deletion of HIF-1α in the intestinal epithelium 
showed a significantly higher susceptibility to orogastric Y enterocolitica 
infections, suggesting HIF-1 activation as a host defense mechanism in this 
model. Additional studies with Y enterocolitica, S enterica subsp enterica, or E 
aerogenes, and, moreover, application of their siderophores (yersiniabactin, 
salmochelin, aerobactin) caused a robust, dose-dependent HIF-1 response in 
human epithelia and endothelia, independent of cellular hypoxia.  
Taken together, such studies demonstrate a role for bacterial siderophores in 
hypoxia-independent activation of HIF-1 during infection with human 
pathogenic bacteria (56).  
Similarly, previous studies on viral infections with RSV have demonstrated 
induction of HIF-1α in primary human bronchial epithelial cells via a nitric-
oxide-dependent pathway (72).  
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Other studies have identified a crosstalk between viral genes and the HIF-1α 
pathway during infections with the human herpesvirus 8 (HHV-8) (19, 157). 
Kaposi's sarcoma-associated herpesvirus (KSHV or HHV-8) is the etiological 
agent of Kaposi's sarcoma, a highly vascularized, endothelial-derived tumor. A 
direct role for KSHV-mediated induction of angiogenesis has been proposed 
based upon the nature of the neoplasia and various KSHV gene 
overexpression and infection model systems. These studies revealed that 
KSHV infection of endothelial cells induces mRNA of HIF-1α and HIF-2α. 
While HIF-1 is classically activated posttranscriptionally, these studies 
demonstrate that both alpha-subunits are up-regulated at the transcript level 
by KSHV infection. 
Infections with B henselae in previous studies resulted in increased oxygen 
consumption and cellular hypoxia in the infected host cells. It was assumed 
that stabilization of HIF-1α during a B henselae infection occurs similar to that 
in cells exposed to hypoxia (69).  
Other studies observed the phenomen of bacterial induction of HIF-1α under 
normoxia with different Gram-positive (Staphylococcus aureus) and Gram-
negative (Pseudomonas aeruginosa, Salmonella typhimurium) bacterias (105).  
 
Here, the transcriptional activation of HIF-1 leads to a functional increase in 
HIF-1 activity under normoxic conditions. Infection with RSV was not 
associated with increased oxygen consumption or cellular hypoxia. The HIF-1α 
stabilization and HIF-dependent gene induction during RSV infection occured 
in an oxygen-independent fashion. 
 
7.6 Role of other transcription factors  
Transcription factors are proteins that bind to regulatory sequences, usually in 
the 5’ upstream promoter region of target genes, to influence the rate of gene 
transcription (8). They play a pivotal role in controlling inflammatory gene 
expression.  
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Nuclear factor kappa B (NF-κB) is a transcription factor regulating multiple 
immune and inflammatory responses and the expression of genes involved in 
host defence and chronic inflammation (6). A number of highly inducible genes 
encoding cytokines, chemokines, and acute-phase reactant and adhesion 
molecules contain NF-κB-binding sites in their proximal promoters (9). 
Extracellular stimuli initiate a signaling cascade that leads to rapid 
phosphorylation of cytoplasmatic inhibitors, IκBs (whose members bind and 
specifically inactivate NF-κB), an event coupled with freeing NF-κB to 
translocate to the nucleus, where it binds and activates target genes (64, 68).  
 
Whereas activation of HIF-1 is known to prevent ischemic neuronal damage 
and promote ischemic tolerance, NF-κB seemed to promote inflammation and 
neuronal death after cerebral ischemia (151). Many NF-κB gene products 
result in a positive regulatory loop that amplifies and perpetuates the 
inflammatory response (8). NF-κB activation after focal ischemia was 
suggested to release detrimental consequences (98). In patients with sepsis, 
fatal outcome was predicted by an increase in NF-κB binding activity. 
Nonsurviving septic patients showed increased nuclear binding activity of NF-
κB compared with probes of survivors (14). 
  
A recent study however suggests that NF-κB is a critical transcriptional 
activator of HIF-1 and that basal NF-κB activity is required for HIF-1 protein 
accumulation under hypoxia (108). These results indicate a role of NF-κB in 
HIF-1α induction (64) but defining the relationship between NF-κB and HIF-1α 
has proven elusive. NF-κB and HIF-1α appear to share common regulatory 
pathways (43). This cross-talk is of major importance for disease states 
associated with low-oxygen tension as well as for a variety of acute or chronic 
inflammatory diseases. An improved understanding is challenging and a 
demanding task.  
 
Previous studies showed, that RSV infection rapidly activates the NF-kappaB 
activation pathway (22). Actually, RSV is able to induce NF-κB-binding activity 
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in the lung independently from its ability to replicate (50). In epithelial cells, 
RSV activates nuclear translocation of NF-κB through proteolysis of its 
cytoplasmic inhibitor IkappaB (135).  
 
While more evidence accumulates supporting the significance of transcription 
factors in promoting and curtailing inflammation, the therapeutic targeting of 
individual transcription factors is still at its infancy.  
 
7.7 HIF-1 activation: protective or detrimental?  
From the present studies it remains unclear whether HIF-1 activation during 
RSV infection represents a host-defence mechanism or is an essential part of 
the disease pathogenesis enabling virus uptake or replication. While some 
studies have identified a host-protective role of HIF-1 during inflammation (34, 
66, 67, 94, 133) or infections (56), others have found a contribution of HIF-1 
activation in growth and survival of human pathogens.  
For example, Toxoplasma gondii is an obligate intracellular protozoan 
pathogen. Recent studies revealed that genes mediating cellular responses to 
hypoxia were upregulated in Toxoplasma -infected cells but not in cells 
infected with another intracellular pathogen, Trypanosoma cruzi (13, 140). The 
inducible expression of these genes is controlled by the HIF-1. Additional 
studies revealed that Toxoplasma infection rapidly increased the abundance of 
the HIF-1α and activated HIF-1 reporter gene expression and survival was 
severely reduced in cells targeted for HIF-1α (128). These studies also 
suggested that while HIF-1α was not required for parasite invasion, HIF-1 was 
required for parasite cell division and organelle maintenance, indicating that 
Toxoplasma activates HIF-1 and requires HIF-1 for growth and survival at 
physiologically relevant oxygen levels (13, 128, 140). 
Rupp et al. reported that Chlamydia pneumoniae directly interferes with host 
cell HIF-1α regulation (110). HIF-1α stabilization was essential for efficient 
Chlamydia pneumoniae replicaton in hypoxia.  
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Analyses about changes in tissue barrier function - commonly associated with 
hypoxia of many origins - revealed mutant HIF1α mice conditionally lacking 
intestinal epithelial HIF-1α protected from hypoxia-induced increases in 
intestinal permeability in vivo (109).  
Other studies provide insight into tissue microenvironmental changes during 
model inflammatory bowel diseases (66) and identify HIF-1 as a critical factor 
for barrier protection during mucosal insult. Studies of colitis in mice revealed 
that decreased HIF-1 expression correlates with more severe clinical 
symptoms, while increased HIF levels were protective in the parameters 
mortality, weight loss and colon length (66).  
Another example can be found in the case of human papillomavirus-16, an 
etiologic agent of cervial intestitial neoplasia that, undetected, can progress to 
cervial carcinoma. In advanced cervical cancer lesions, many of which are 
hypoxic, increased HIF-1α levels can be correlated to poor prognosis (11, 59). 
 
The central role of HIF-1α in physiology and pathology makes it an attractive 
yet intricate target for pharmacological manipulations. Because of its perceived 
therapeutic potential it is already increasingly studied. As it causes 
angiogenesis, enhancement of this gene within ischemic patients could 
promote the vessel proliferation needed for oxygenation. In contrast, as HIF-1 
allows for survival and proliferation of cancerous cells due to its angiogenic 
properties, inhibition potentially could prevent the spread of cancer. With a 
growing understanding of the HIF-1 pathway, the inhibition and stimulation of 
its transcriptional activity is now an attractive goal (155). 
 
Understanding the processes of HIF-1 in the oxygen-dependent and oxygen-
independent regulation during inflammatory responses and the role they play 
within inflamed sites may offer new opportunities for therapeutic intervention.  
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7.8 Conclusion 
Taken together, the present studies provide molecular insight into the role of 
HIF-1 as transcriptional control of gene expression and reveal oxygen-
independent stabilization of HIF-1α during RSV infection in vitro and in vivo.  
Future challenges will include the determination whether such responses 
elicited during RSV infections are host-protective or host-detrimental. A better 
understanding of HIF-1α function may provide novel and rational approaches 
for boosting innate immune function in the therapy of certain complicated 
infectious disease conditions. Ongoing studies are currently testing HIF-
activation or HIF-inhibition in different settings of medical therapy and novel 
therapeutics will soon become available in patient care to inhibit or to activate 
the HIF-1 pathway. Such compounds may comprise a novel approach during 
RSV infections. 
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8 Summary 
Hypoxia-inducible factor 1 (HIF-1) is a transcription factor that functions as 
master regulator of mammalian oxygen homeostasis. In addition, recent 
studies identified a role for HIF-1 as transcriptional regulator during 
inflammation or infection. Based on studies showing that respiratory syncytial 
virus (RSV) is among the most potent biological stimuli to induce an 
inflammatory milieu, we hypothesized a role of HIF-1 as transcriptional 
regulator during infections with RSV. 
 
We gained first insight from immunohistochemical studies of RSV-infected 
human pulmonary epithelia that were stained for HIF-1α. These studies 
revealed that RSV-positive cells also stained for HIF-1α, suggesting 
concomitant HIF-activation during RSV infection. Similarly, Western blot 
analysis confirmed an approximately 7-fold increase in HIF-1α protein 24h 
after RSV infection. In contrast, HIF-1 activation was abolished utilizing UV-
treated RSV. Moreover, HIF-regulated genes (VEGF, CD73, FN-1, COX-2) 
were induced with RSV infection of wildtype cells. In contrast, HIF-1 dependent 
gene induction was abolished in pulmonary epithelia following siRNA mediated 
repression of HIF-1α. Measurements of the partial pressure of oxygen in the 
supernatants of RSV infected epithelia showed no differences in oxygen 
content, suggesting that HIF-1 activation is not caused by RSV associated 
hypoxia. Finally, studies of RSV pneumonitis in mice confirmed HIF-activation 
in a murine in vivo model. 
 
Taking together, these studies suggest hypoxia-independent activation of HIF-
1 during infection with RSV in vitro and in vivo. 
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9 Data tables 
Figure 2 C 
 Least Sq Mean Lower 95% Upper 95% 
RSV 7.15 3.13 16.30 
UV-RSV 0.84 0.37 1.92 
Hypoxia 5.70 2.50 13.01 
 
 
Figure 3 A-D 
 Least Sq Mean Lower 95% Upper 95% 
3A, MOI 1 3.20 2.24 4.57 
3A, MOI 3 3.95 2.77 5.64 
3A, MOI 5 3.29 2.30 4.69 
    
3B, MOI 1 1.60 1.16 2.20 
3B, MOI 3 2.50 1.75 3.56 
3B, MOI 5 2.42 1.70 3.46 
    
3C, MOI 1 2.63 1.91 3.61 
3C, MOI 3 2.18 1.58 2.30 
3C, MOI 5 2.45 1.78 3.37 
    
3D, MOI 1 2.88 2.09 3.96 
3D, MOI 3 3.59 2.61 4.94 
3D, MOI 5 4.35 3.16 5.98 
 
 
Figure 4 A-C 
 Least Sq Mean Lower 95% Upper 95% 
4A, UV-RSV 1.10 0.77 1.58 
4A, MOI 1 1.72 1.20 2.47 
4A, MOI 3 1.97 1.37 2.83 
4A, MOI 5 2.85 1.98 4.09 
    
4B, UV-RSV 1.33 0.71 2.47 
4B, MOI 1 1.74 0.94 3.25 
4B, MOI 3 2.53 1.36 4.72 
4B, MOI 5 3.45 1.85 6.43 
    
4C, MOI 1 1.33 1.17 1.51 
4C, MOI 3 1.65 1.45 1.87 
4C, MOI 5 1.56 1.40 1.75 
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Figure 5 B-E 
 Least Sq Mean Lower 95% Upper 95% 
5B, Control siRNA 24h 6.19 4.53 8.46 
5B, HIF-1 α siRNA 24h 1.11 0.81 1.51 
5B, Control siRNA 48h 4.71 3.45 6.44 
5B, HIF-1 α siRNA 48h 1.35 0.99 1.84 
    
5C, Control HIF- 0.72 0.40 1.29 
5C, RSV MOI3 scr 2.08 1.16 3.75 
5C, RSV MOI3 HIF- 1.05 0.58 1.88 
    
5D, Control HIF- 1.29 0.57 2.96 
5D, RSV MOI 3 scr 6.12 2.65 14.13 
5D, RSV MOI 3 HIF- 2.43 1.05 5.62 
    
5E, Control HIF- 0.70 0.23 2.15 
5E, RSV MOI 3 scr 4.28 1.40 13.09 
5E, RSV MOI 3 HIF- 1.17 0.38 3.58 
 
 
Figure 6 A-D 
 Least Sq Mean Lower 95% Upper 95% 
6A, UV-RSV MOI 3 1.28 0.83 1.97 
6A, RSV MOI 3 2.50 1.72 3.62 
    
6B, UV-RSV MOI 3 1.33 1.06 1.66 
6B, RSV MOI 3 4.01 3.09 5.22 
    
6C, UV-RSV MOI 3 1.06 0.72 1.54 
6C, RSV MOI 3 2.17 1.43 3.29 
    
6D, UV-RSV MOI 3 1.08 0.79 1.49 
6D, RSV MOI 3 3.74 2.63 5.30 
 
 
Figure 7 
 Parameter Estimate Lower CL Upper CL 
Control α    0.11 0.06 0.19 
MOI 1 α    0.08 0.04 0.12 
MOI 5 α    0.09 0.03 0.14 
Control bo 199.12 189.33 209.31 
MOI 1 bo 192.80 186.00 199.78 
MOI 5 bo 192.11 182.53 202.06 
Control  b1    110.86 80.49 126.24 
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MOI 1 b1   96.28 55.13 113.80 
MOI 5 b1   94.55 8.68 117.14 
 
 
Figure 8 
 Least Sq Mean    Lower 95% Upper 95% 
+ RSV 12h 4.52  2.14     9.56 
+ RSV 24h 3.25   1.54      6.88 
+ RSV 48h 4.01 1.90  8.48 
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